The function of ATP binding cassette protein A1 (ABCA1) is central to cholesterol
mobilization. Reduced ABCA1 expression or activity is implicated in Alzheimer's disease …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which no
cognition-restoring therapies exist. Gamma-aminobutyric acid (GABA) is the primary …

Background Hypothalamic dysfunction occurs early in the clinical course of Alzheimer's
disease (AD), likely contributing to disturbances in feeding behavior and metabolic function …

Alzheimer's disease (AD) is the most common neurodegenerative disease, yet there are no
disease-modifying treatments available and there is no cure. It is becoming apparent that …

Previous studies have shown significant changes in amyloid-β (Aβ) transport across the
blood–brain barrier (BBB) under diabetic conditions with hypoinsulinemia, which is involved …

Amyloid-beta (Aβ) peptides, Aβ 1–42 (Aβ42) and Aβ43, in particular, have been implicated
in the pathophysiology of neurodegenerative disease such as Alzheimer's disease (AD) …

α1-adrenergic receptors are G-Protein Coupled Receptors that are involved in
neurotransmission and regulate the sympathetic nervous system through binding and …

Progressive decrease in neuronal function is an established feature of Alzheimer's disease
(AD). Previous studies have shown that amyloid β (Aβ) peptide induces acute increase in …

It is widely accepted that high calorie diets and a sedentary lifestyle sturdily influence the
incidence and outcome of type 2 diabetes and obesity, which can occur simultaneously, a …

Current therapies for Alzheimer's disease (AD) offer partial symptomatic relief and do not
modify disease progression. There is substantial evidence indicating a disease onset years …